Drug discovery today.
Publisher:
Elsevier Science Ltd. ;
Frequency: Twenty-four no. a year, 2001-
Country: England
Language: English
Start Year:1996 -
ISSN:
1359-6446 (Print)
1878-5832 (Electronic)
1359-6446 (Linking)
1878-5832 (Electronic)
1359-6446 (Linking)
Impact Factor
7.4
2022
| NLM ID: | 9604391 |
| (DNLM): | SR0085684(s) |
| (OCoLC): | 34182620 |
| Coden: | DDTOFS |
| LCCN: | sn 96000066 |
| Classification: | W1 DR521CX |
New trends for osteoarthritis: Biomaterials, models and modeling. The burden of osteoarthritis (OA), one of the major causes of functional disabilities in humans and animals, continues to increase worldwide while no disease-modifying OA drugs (DMOADs) that either slow down or reverse disease progression have been made available. Here, we provide a brief overview of recent advances in: designing new OA drug delivery approaches, focusing on lubrication-based biomaterials and drug delivery systems, such as hydrogels, liposomes, dendrimers, micro- and nanoparticles; using either large (horse) or small (zebrafish) relevant animal models to evaluate new therapeuti...
Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs. The advanced therapy medicinal products (ATMPs) landscape is entirely different from classical drug development. Academia has been the major source of ATMP development, and academic hospitals act as trial sites for the clinical testing of ATMPs, including early academic-led trials as well as industry-sponsored trials that pursue the full developmental pathway to market authorization. The recent breakthrough developments in some ATMPs, such as genetically engineered immune cells, have confronted academic hospitals with a substantial amount of public demand, competitive pressure, and costs. At t...